4519 — Chugai Pharmaceutical Share News
0.000.00%
Last trade - 00:00Japan's Chugai Pharmaceutical hits record high; technicals point to more upside
Brief: Chugai Pharmaceutical Says Tecentriq Approved As Lung Cancer Treatment In Japan
Table: Chugai Pharm -6-MTH group results (IFRS)
Graphic: Japan's polarised stock market leaves few options for investors
Brief: Chugai Obtains Approval Of FoundationOne CDx Cancer Genomic Profile As A Companion Diagnostic For Rozlytrek
Tokyo District Court Renders Judgment On The Patent Infringement Lawsuit Concerning Rituxan® Injection
Brief: Chugai Pharmaceutical To Construct New Manufacturing Building For Active Pharmaceutical Ingredients For Clinical Studies
Table: Chugai Pharm -Q1 group results (IFRS)
Brief: Chugai Pharmaceutical Co Conclusion Of Exclusive Licensing And Capital Tie-Up Agreements Concerning "Telomelysin (Obp-301)," Oncolytic Viral Immunotherapy
Brief: Chugai Pharmaceutical Says It And Miraca Enter Into Business Partnership Agreement For "Foundationone Cdx Cancer Genome Profile"
Table: Chugai Pharm -2018 group results (IFRS)
Brief: Chugai Pharmaceutical Transfers Rights To Maruho For Oxarol Ointment, Oxarol Lotion And Marduox Ointment
Brief: Chugai Pharmaceutical Completes Transfer Of Marketing And Manufacturing Rights Of 13 Long-Term Listed Products From Chugai To Taiyo Pharma
Brief: Chugai: Files Lawsuit Against Alexion For Infringement Of Its Proprietary Antibody Engineering Technology In Japan
Brief: Alexion Opposes Claims Against Co Filed By Chugai Pharmaceutical
Brief: Chugai Files Lawsuit Against Alexion Alleging Infringement Of Its Proprietary Antibody Engineering Technology In U.S.
Table: Chugai Pharm -9-MTH group results (IFRS)
Brief: Chugai Pharmaceutical says lawsuit on patent infringement concerning herceptin® injection
Brief: Chugai Pharmaceutical and Lilly enter into license agreement for oral GLP-1 agonist, OWL833